Common Equity: The sum of all common equity items.
Avalo Therapeutics, Inc. (AVTX) had Common Equity of $91.55M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-30.62M |
|
-- |
|
-- |
|
$19.20M |
|
$-19.20M |
|
$-11.42M |
|
$-30.61M |
|
$-30.61M |
|
$-30.62M |
|
$-30.62M |
|
$-30.62M |
|
$-30.62M |
|
$-19.20M |
|
$-19.14M |
|
14.00M |
|
14.00M |
|
$-2.19 |
|
$-2.19 |
|
| Balance Sheet Financials | |
$113.85M |
|
$0.54M |
|
$11.25M |
|
$125.10M |
|
$7.97M |
|
-- |
|
$25.58M |
|
$33.55M |
|
|
Common Equity |
$91.55M |
$81.05M |
|
$91.55M |
|
17.83M |
|
| Cash Flow Statement Financials | |
$-37.21M |
|
$-84.12M |
|
$13.90M |
|
$134.70M |
|
$27.26M |
|
$-107.43M |
|
$9.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.45% |
|
-37.79% |
|
-24.48% |
|
-33.45% |
|
$5.13 |
|
$-2.66 |
|
$-2.66 |
|